• Frequent plateletpheresis is associated with lymphopenia, sometimes severe but a robust immune response to vaccine neoantigens is maintained.

  • Frequent donations and lower total lymphocyte or lower CD4 counts at baseline were not associated with lower vaccine responses.

Frequent plateletpheresis is associated with severe lymphopenia of uncertain clinical significance. We assessed the functional impact of frequent platelet donations and associated lymphopenia on the response to neoantigens. We conducted a prospective study of 102 platelet donors (HIV uninfected) who were naive to meningococcal vaccination recruited at Brigham and Women’s Hospital. One dose of quadrivalent meningococcal conjugate vaccine was administered. Seroresponse was defined as a fourfold increase of serum bactericidal antibody titers and seroprotection was defined as postvaccination titers of ≥1:8, for each of the 4 vaccine antigens (A, C, W, and Y). Mean age of participants was 61 years, 69% were male, and medial number of platelet donations in prior year was 14 (interquartile range, 4-20). Frequent platelet donors had a low CD4 count (14% with ≤200/μL and 34% with ≤350/μL). Seroresponse rates varied from 68% for serogroup Y to 86% for serogroup A and were higher for participants with baseline titers of <1:8. Postvaccination seroprotection rates varied from 76% for serogroup Y to 96% for serogroup A. After adjustments for age, sex, and frequent donations, lower total lymphocyte or lower CD4 counts were not associated with lower responses. These data suggest no impairment by plateletpheresis-associated lymphopenia on response to these neoantigens. This trial was registered at www.clinicaltrials.gov as #NCT04224311.

1.
Heddle
NM
,
Blajchman
MA
,
Meyer
RM
, et al
.
A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets
.
Transfusion
.
2002
;
42
(
5
):
556
-
566
.
2.
Trial to Reduce Alloimmunization to Platelets Study Group
.
Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions
.
N Engl J Med
.
1997
;
337
(
26
):
1861
-
1869
.
3.
Food and Drug Administration
.
Guidance for Industry and FDA Review Staff: Collection of Platelets Pheresis
. 1988. https://www.fda.gov/media/70852/download.
4.
Food and Drug Administration
.
Guidance for Industry and FDA Review Staff: Collection of Platelets by Automated Methods
. 2007. https://www.fda.gov/media/70720/download.
5.
Gansner
JM
,
Rahmani
M
,
Jonsson
AH
, et al
.
Plateletpheresis-associated lymphopenia in frequent platelet donors
.
Blood
.
2019
;
133
(
6
):
605
-
614
.
6.
Andrews
N
,
Borrow
R
,
Miller
E
.
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England
.
Clin Diagn Lab Immunol
.
2003
;
10
(
5
):
780
-
786
.
7.
Borrow
R
,
Aaberge
IS
,
Santos
GF
, et al
.
Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine
.
Clin Diagn Lab Immunol
.
2005
;
12
(
8
):
970
-
976
.
8.
Borrow
R
,
Balmer
P
,
Miller
E
.
Meningococcal surrogates of protection--serum bactericidal antibody activity
.
Vaccine
.
2005
;
23
(
17-18
):
2222
-
2227
.
9.
Thuer
L
,
Brosig
A
,
Hutchinson
JA
, et al
.
Total platelet donation count and donation frequency are determinants of plateletpheresis-associated lymphopenia
.
Transfusion
.
2021
;
61
(
11
):
3161
-
3173
.
10.
Zhao
J
,
Gabriel
E
,
Norda
R
, et al
.
Frequent platelet donation is associated with lymphopenia and risk of infections: a nationwide cohort study
.
Transfusion
.
2021
;
61
(
2
):
464
-
473
.
11.
Rahmani
M
,
Fortin
BM
,
Berliner
N
, et al
.
CD4+ T-cell lymphopenia in frequent platelet donors who have ceased platelet donation for at least 1 year
.
Transfusion
.
2019
;
59
(
5
):
1644
-
1647
.
12.
Gansner
JM
,
Papari
M
,
Goldstein
J
, et al
.
Severe CD4+ T-cell lymphopenia is not observed in frequent plateletpheresis donors collected on the Fenwal Amicus
.
Transfusion
.
2019
;
59
(
9
):
2783
-
2787
.
13.
Laumaea
AE
,
Lewin
A
,
Chatterjee
D
, et al
.
COVID-19 vaccine humoral response in frequent platelet donors with plateletpheresis-associated lymphopenia
.
Transfusion
.
2022
;
62
(
9
):
1779
-
1790
.
14.
Cheng
MP
,
Pandit
A
,
Antin
JH
, et al
.
Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation
.
Blood Adv
.
2018
;
2
(
11
):
1272
-
1276
.
15.
Wyplosz
B
,
Derradji
O
,
Hong
E
, et al
.
Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients
.
Transpl Infect Dis
.
2015
;
17
(
2
):
322
-
327
.
16.
Bertolini
DV
,
Costa
LS
,
van der Heijden
IM
,
Sato
HK
,
Marques
HH
.
Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults
.
Vaccine
.
2012
;
30
(
37
):
5482
-
5486
.
18.
Exploratory trial to evaluate the safety and immunogenicity of menactra and menomune vaccines in subjects ≥ 56 years. ClinicalTrials.gov identifier: NCT00874549
. Updated 20 September 2013. Accessed 20 March 2023. https://clinicaltrials.gov/ct2/show/NCT00874549.
19.
Chen
WH
,
Neuzil
KM
,
Boyce
CR
, et al
.
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study
.
Lancet Infect Dis
.
2018
;
18
(
10
):
1088
-
1096
.
20.
Dhingra
MS
,
Peterson
J
,
Hedrick
J
,
Pan
J
,
Neveu
D
,
Jordanov
E
.
Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study
.
Vaccine
.
2020
;
38
(
33
):
5194
-
5201
.
You do not currently have access to this content.
Sign in via your Institution